Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2009

Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
DRUG

M200 (Volociximab)

7.5 mg/kg, IV infusion every week until disease progression

DRUG

Liposomal Doxorubicin

40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

DRUG

M200 (Volociximab)

15 mg/kg, IV infusions every week until disease progression

DRUG

M200 (Volociximab)

15 mg/kg, IV infustions every other week until disease progression

Trial Locations (39)

1200

Site Reference ID/Investigator# 75336, Brussels

2020

Site Reference ID/Investigator# 75337, Antwerp

3000

Site Reference ID/Investigator# 75338, Leuven

5011

Site Reference ID/Investigator# 75335, Woodville South

5065

Site Reference ID/Investigator# 75334, Toorak Gardens

6500

Site Reference ID/Investigator# 75416, Bellinzona

17007

Site Reference ID/Investigator# 75350, Girona

17176

Site Reference ID/Investigator# 75354, Stockholm

20133

Site Reference ID/Investigator# 75415, Milan

20141

Site Reference ID/Investigator# 75333, Milan

21215

Site Reference ID/Investigator# 75274, Baltimore

23185

Site Reference ID/Investigator# 75297, Danville

Site Reference ID/Investigator# 75298, Williamsburg

28040

Site Reference ID/Investigator# 75353, Madrid

30309

Site Reference ID/Investigator# 75299, Atlanta

31404

Site Reference ID/Investigator# 75300, Savannah

33323

Site Reference ID/Investigator# 75296, Sunrise

54301

Site Reference ID/Investigator# 75278, Green Bay

60521

Site Reference ID/Investigator# 75301, Hinsdale

65109

Site Reference ID/Investigator# 75294, Jackson

73104

Site Reference ID/Investigator# 75279, Oklahoma City

75246

Site Reference ID/Investigator# 75280, Dallas

78404

Site Reference ID/Investigator# 75295, Corpus Christi

90277

Site Reference ID/Investigator# 75275, Redondo Beach

92801

Site Reference ID/Investigator# 75281, Anaheim

129128

Site Reference ID/Investigator# 75346, Moscow

143423

Site Reference ID/Investigator# 75348, Moscow

198255

Site Reference ID/Investigator# 75347, Saint Petersburg

15-027

Site Reference ID/Investigator# 75344, Bialystok

31-531

Site Reference ID/Investigator# 75339, Krakow

20-090

Site Reference ID/Investigator# 75341, Lublin

61-001

Site Reference ID/Investigator# 75342, Poznan

61-848

Site Reference ID/Investigator# 75343, Poznan

70-111

Site Reference ID/Investigator# 75345, Szczecin

50-367

Site Reference ID/Investigator# 75340, Wroclaw

08035

Site Reference ID/Investigator# 75349, Barcelona

08036

Site Reference ID/Investigator# 75351, Barcelona

08208

Site Reference ID/Investigator# 75352, Barcelona

901 85

Site Reference ID/Investigator# 75355, Umeå

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00635193 - Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | Biotech Hunter | Biotech Hunter